Effectiveness of Intravitreal Ranibizumab in Nonvitrectomized and Vitrectomized Eyes with Diabetic Macular Edema: A Two-Year Retrospective Analysis

Table 3

Effect of treatment on BCVA, CMT, and TMV values in the nonvitrectomized group (n = 17).

	Mean ± SD	F value	value	Partial eta^2
BCVA (logMAR)
Baseline	0.51 ± 0.26	4.645	0.002	0.225
6^th month	0.39 ± 0.26
12^th month	0.41 ± 0.25
18^th month	0.41 ± 0.24
24^th month	0.40 ± 0.22
CMT (μm)
Baseline	342 ± 98	4.648	0.002	0.225
6^th month	288 ± 93
12^th month	266 ± 111
18^th month	288 ± 97
24^th month	253 ± 97
TMV (mm^3)
Baseline	9.04 ± 1.28	7.363	0.001	0.315
6^th month	8.43 ± 1.04
12^th month	8.36 ± 1.10
18^th month	8.40 ± 0.95
24^th month	8.01 ± 0.79

BCVA was measured with a standard Snellen chart and converted to the logarithm of the minimum angle of resolution (logMAR) units. BCVA indicates best-corrected visual acuity; CMT, central macular thickness; SD, standard deviation; TMV, total macular volume. Repeated measure ANOVA. Other than BCVA values from baseline to the 6th month of treatment, CMT values from baseline to the 12th month of the treatment, and TMV values from baseline to the 12th month and from baseline to the 24th month of the treatment, pairwise comparisons for BCVA, CMT, and TMV values were not significant in the nonvitrectomized group.